Safety and effectiveness of the anti‐amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: the pharmacovigilance perspective

Amy Bobbins, Miranda Davies, Elizabeth Lynn, Debabrata Roy, Alison Yeomans, Saad A. W. Shakir

Research output: Contribution to journal › Article › peer-review

2 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Safety and effectiveness of the anti‐amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: the pharmacovigilance perspective'. Together they form a unique fingerprint.

INIS

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science